28 February is Rare Disease Day, and we proudly support this globally-coordinated movement working towards equity in social opportunity, healthcare, and access to diagnosis and therapies for people living with a rare disease.
This year's video features stories of real people all around the world who are living with a rare disease.
Watch the video:
At Quanticate, we have worked on various rare disease studies. We have recently supported an orphan drug application by providing both statistical and medical writing activities to a study investigating the safety and efficacy to treat acute attacks in patients with hereditary angioedema.
We also have experience in estimating prevalence for an orphan drug application in Parkinson's disease and head and neck cancers.
Here is some additional rare disease work that our teams have been working on:
Cholestatic pruritus in subjects with PBC
Dengue virus infection
Haemophilia B studies
Duchenne's muscular dystrophy
Focal segmental glomerulosclerosis (FSGS)
Growth Hormone Deficiency studies
Would you like to know more about our Rare Disease activity? You can contact our team to discuss any enquiry you have by clicking here.
You can also watch our free on-demand webinar on Gene Therapy for Rare Diseases: Considerations for both Clinical and Post-Marketing Studies. Our speakers, Karen Ooms and David Hukin examine the challenges of rare diseases focusing on gene therapy treatments.
Quanticate meets the needs of drug‑ and device‑development companies by offering customer‑focused resource solutions from fixed‑cost orfunctional‑service‑provider (FSP) modelsthrough to consultancy. Quanticate has become the trusted supplier of choice for many companies from niche biotechnology and device companies to top tier pharmaceutical giants.